Introduction
============

Healthy bone remodeling is a result of balanced bone formation realized bone-forming osteoblasts and bone-resorption mediated by bone resorbing osteoclasts ([@B11]). Recently, Thy-1 (CD90) was identified as a critical molecule for the differentiation of osteoblasts and, thus, promoting osteogenesis and bone formation while inhibiting adipogenesis and obesity. Thy-1 is a glycosylphosphatidyl-anchored protein located on the cell surface of mesenchymal stem cells (MSCs), fibroblasts, activated microvascular endothelial cells, neurons, a subpopulation of hematopoietic stem cells (HSCs) and mouse T-cells ([@B50]; [@B10]; [@B51]; [@B43]; [@B39]). Recently, it was discovered that Thy-1 controls fate decision of MSCs regarding differentiation into mature bone-forming osteoblasts or fat-storing adipocytes *in vitro* and *in vivo* ([@B19]; [@B8]; [@B52]; [@B34]; [@B39]). Mice lacking Thy-1 display a reduced osteogenic and increased adipogenic differentiation capacity, resulting in decreased bone mass and quality and concurrently, elevated body and bone marrow fat mass ([@B52]; [@B34]; [@B39]). Reduced osteogenesis in Thy-1 deficiency was linked to increased serum concentrations of the Wnt signaling inhibitors Dickkopf-1 (Dkk-1) and sclerostin, diminished Wnt ligand expression and attenuated Wnt signaling ([@B39]). However, Thy-1 did not affect bone resorption in lean mice. The translational potential of these findings was underlined by the detection of strongly reduced levels of soluble Thy-1 in serum of patients with diminished bone formation such as in osteoporotic and obese patients ([@B39]).

Worldwide, obesity is a major health problem negatively affecting bone metabolism. Obese patients often show increased bone mass and paradoxically suffer from an highly elevated fracture risk ([@B28]; [@B15]). Interestingly, in obesity bone remodeling is elevated in early phases due to increased mechanical loading by high body weight, which results in elevated bone mass ([@B15]). Later on, the massive amount of adipose tissue, especially bone marrow fat and visceral fat depots, leads to an increased production of pro-inflammatory cytokines such as tumor necrosis factor α (TNFα) and interleukin 6 (IL-6) resulting in chronic inflammatory response ([@B20]; [@B44]; [@B35]). This abnormal cytokine production results in altered bone mass and highly increased fracture risk in obese patients ([@B21]; [@B32]; [@B15]; [@B35]).

Tumor necrosis factor α has the potential to increase the osteogenic differentiation capacity of MSCs or to reduce the osteogenic differentiation of pre-osteoblasts, which have already started their differentiation process ([@B13]; [@B33]). In addition, TNFα also promotes the differentiation of HSCs into osteoclasts by promoting actin ring formation and inducing an elevated secretion of receptor activator of NF-κB ligand (RANKL) by osteoblasts ([@B12]; [@B33]). RANKL binds to its receptor RANK, located at the surface of osteoclast precursor cells, resulting in an increase in osteoclastogenesis. TNFα and RANKL have also been shown to operate synergistically on osteoclastogenesis by increasing RANK expression via TNF type 1 receptor (TNFR1) signaling ([@B54]). In addition, CSF1, produced by osteoblasts, supports the positive effect of TNFα on osteoclastogenesis. Consequently, inhibition of CSF-1 in mice resulted in reduced osteoclastogenesis and osteolysis ([@B27]). Osteoblasts also produce osteoprotegerin (OPG), a decoy receptor of RANKL, and can therefore inhibit osteoclast differentiation ([@B4]). In mice, high fat diet (HFD) reduces bone mass due to increased bone marrow adipogenesis and osteoclastogenesis mediated by higher levels of TNFα, RANKL, and PPARγ ([@B45]). The underlying mechanisms of HFD induced bone alterations are not yet fully elucidated and therefore, therapy options for efficient bone-anabolic treatments are limited ([@B49]).

In the present study, we analyzed the impact of Thy-1 on disturbed bone metabolism in obesity. Thy-1-deficient (Thy-1^−/−^) and wildtype (WT) mice were fed with a HFD to induce obesity. We detected a reduced number and activity of osteoblasts resulting in a decreased bone formation in obese Thy-1^−/−^ mice. In parallel, in obese Thy-1^−/−^ mice, osteoclast number and activity were increased. An elevated bone marrow adiposity associated with an increased pro-inflammatory environment including increased *TNFa* and *Csf1r* expression and an attenuated gene expression of OPG (*Tnfsf11B*), the decoy receptor for RANKL (*Tnfsf11*) in obese Thy-1^−/−^ mice contributed to strengthened bone resorption. Thus, under obese conditions, Thy-1 affects both the osteo-anabolic and -catabolic metabolism.

Materials and Methods {#s1}
=====================

Mice
----

Thy-1 deficient (KO) mice on C57BL/6J background \[kindly provided as a gift from Dr. R. Morris King's College London, (61)\] and C57BL/6J wildtype (WT) mice were kept under a 12-h light-dark cycle and given food and water *ad libitum*. All animal experiments were performed in accordance with institutional and state guidelines and approved by the Committee on Animal Welfare of Saxony (TVV 03/16, T26/16). Four to five weeks old male C57BL/6J mice were fed a HFD (EF R/M D12331 diet modified by Surwit, ssniff, Soest, Germany). The second cohort (**Supplementary Figure [1](#SM1){ref-type="supplementary-material"}**; [@B39]) were fed a standard chow until the age of 12 weeks.

RNA Isolation, RT, and Quantitative Real Time PCR (qRT-PCR)
-----------------------------------------------------------

Total RNA from bone samples (ulnae) was isolated using a Trifast (PEQLAB, United States) method following the manufacturer's instructions. For first strand cDNA synthesis with M-MLV reverse transcriptase (Promega, Madison, WI, United States), 1 μg total RNA was used according to the manufacturer's protocol. Using *GoTaq^®^ qPCR Master* (Promega) the real-time qPCR was performed according to the manufacturer's instructions on Rotor-Gene Q (QIAGEN). Used primers are listed in **Supplementary Table [1](#SM1){ref-type="supplementary-material"}**. Quantitative gene expression was calculated from the standard curve of cloned cDNA and was normalized to the unregulated reference genes *Rs36* (*ex vivo* cell culture) *or Gapdh* (bones).

Serum Analysis
--------------

Blood was drawn by heart puncture, centrifuged and frozen at −80°C. Serum levels of type 1 procollagen amino-terminal propeptide (P1NP), C-terminal telopeptide (CTX and P1NP: Immundiagnostik Systems, Germany), sclerostin (ALPCO, serum dilution 1:5), and Dkk-1 (R&D) were detected using immunoassay kits according to the manufacturer's protocols.

Assessment of Bone Mass, Microarchitecture, and Bone Marrow Fat Volume
----------------------------------------------------------------------

Extracted bones were fixed for 48 h in 4% paraformaldehyde (PFA, Carl Roth, Karlsruhe, Germany) and were afterward dehydrated in 80% ethanol. By using the μCT vivaCT 40 (isotropic voxel size of 10.5 μm; 70 kVp, 114 μA, 200 ms integration time, Scanco Medical, Switzerland), femora and third lumbar vertebral bodies were analyzed as previously described ([@B39]). The analysis of trabecular and cortical bone volume per total volume (BV/TV), bone mineral density (BMD), thickness (Tb.Th and Ct.Th for the trabecular and cortical thickness, respectively), trabecular number (Tb.N), trabecular separation (Tb.Sp) and cortical porosity (Ct.Po) was performed using established analysis protocols and the μCT parameters were reported according to international guidelines (63). To analyze the total area (Tt.Ar), marrow area (Ma.Ar) and cortical bone area (Ct.Ar) the periosteal and endosteal surfaces at the femoral mid-shaft were identified and afterward computed as the area within the periosteal boarder, the area within the endosteal border, and the area between the periosteal and endosteal borders, respectively ([@B39]). Animations of the trabecular microstructure were generated from the Digital Imaging and Communications in Medicine (DICOM) image files in Amira (v6.0.0, Thermo Fisher Scientific, Hillsboro, OR, United States) and saved in gif format using ImageJ (v 1.46 r, NIH, United States; see **Supplementary Animation [1](#SM2){ref-type="supplementary-material"}** of the trabecular bone compartment of femur of either WT or KO mice).

For assessment of the bone marrow fat content, fixed femora were decalcified (OSTEOSOFT^®^) for seven d and afterward scanned via μCT to ensure complete decalcification. They were then washed with PBS for 5 min, stained for 2 h with 2% osmium tetroxide (Electron Microscopy Science, United Kingdom) diluted in 0.1 M sodium cacodylate buffer (pH 7.4) ([@B40]), and were transferred into PBS. The complete femur was analyzed with μCT (70 kVp, 114 μA, 300 ms integration time, 10.5 μm isotropic voxel size) to evaluate the fat volume using the established protocols from Scanco Medical as previously reported e ([@B39]).

Fourier-Transform Infrared Spectroscopy (FTIR) Analysis
-------------------------------------------------------

Fourier-transform infrared spectroscopy spectra was measured at a Spotlight 400 (PerkinElmer, Waltham, MA, United States) attached to a Frontier FTIR spectrometer (PerkinElmer, Waltham, MA, United States) in ATR-mode. Spectra were acquired within a wavelength range from 4000 to 570 cm^−1^ with a resolution of 4 cm^−1^. For each pixel (6.25 μm × 6.25 μm), 16 measurements were taken. SpectrumIMAGE software R.1.8.0.0410 (PerkinElmer, Waltham, MA, United States) was used for automatic background subtraction for each pixel spectrum and for automatic ATR correction. Each region of interest was 300 × 300 μm^2^ in size and included the whole cortical thickness. The spectra were post processed using a customized MATLAB (MATLAB 2014b, The MathWorks, Inc., MA, United States) routine with PMMA subtraction and baseline correction. Crystallinity was calculated by sub-peak fitting of the entire phosphate peak (1154--900 cm^−1^) and calculation of the ratio of the 1030 and 1020 cm^−1^ sub-peaks (27). The sub-peak of 1020 cm^−1^ is linked to non-stoichiometric apatite, whereas the sub-peak of 1030 cm^−1^ is linked to stoichiometric apatite (64). An increase of the crystallinity ratio reflects either an increase of stoichiometric apatite or a decrease of non-stoichiometric apatite (i.e., the crystallinity ratio reflects crystal size and perfection).

Reference-Point Analysis, Three-Point Bending Test, and Femur Properties
------------------------------------------------------------------------

The femora were shock frozen in liquid nitrogen after sacrifice and thawed from −80°C 5 min before reference-point indentation^TM^ (BioDent2, Active Life Scientific, United States). To avoid sample drying the bones were stabilized using an *ex vivo* small bone stage, which was filled with PBS. The reference probe was located at the anterior side of the femur shaft and indentation measurements were performed (2 N, five cycles) in triplicates for each bone sample by lifting up the measurement head unit and keeping the movement of the sample to a minimum. The total distance increase (TDI) was calculated. Promptly afterward, the femora were mechanically tested in a three-point bending (zwicki-Line 2.5 kN, Zwick, Germany). Load was applied at the anterior site of the femoral shaft until failure and the maximum load (F~max~, N) was recorded as previously reported ([@B40], [@B39]). The length (proximal to distal: greater trochanter to condyles) and width (shaft) of femora were measured using a caliper.

Bone Histology and Histomorphometry
-----------------------------------

WT and Thy-1-deficient mice received i.p. injections of calcein (20 mg/kg) 5 and 2 days prior to sacrifice as previously reported ([@B39]). The right and left proximal tibia were fixed in 4% PFA and dehydrated with 80% ethanol. For examination of bone formation rate by analysis of calcein labels (fluorescence), left tibiae were embedded in methyl methacrylate (Technovit 9100, Heraeus Kulzer, GER) and cut into 7-μm sections. BV/TV, bone formation rate per bone surface (BFR/BS), mineralized surface per BS (MS/BS), and mineral apposition rate (MAR) were determined in the trabecular part of the bone using the OsteoMeasure^®^ Software (OsteoMetrics, Atlanta, GA, United States) following the international standards ([@B37]). Mineralized bone areas (BV/TV) and osteoid surface per bone perimeter (Osteoid.S/B.Pm) were visualized by *von Kossa* staining and *van Gieson* counter staining. Therefore, bone sections were rehydrated using decreasing alcohol concentrations and were then sequentially exposed to silver nitrate (Roth), sodium carbonate (Merck), and sodium thiosulfate (Roth). Afterward, the slides were stained with toluidine blue (Waldeck GmbH, Germany) and dehydrated. The right proximal tibiae were then decalcified using OSTEOSOFT^®^ and embedded in paraffin (Leica Biosystems, United States) for the analysis of osteoclast numbers per bone surface (Oc.N/BS) and osteoclast surface per bone perimeter (Oc.S/B.Pm). Bone slices of 2 μm were stained at 37°C with tartrate resistant acid phosphatase (TRAP) staining solution (Naphthol-AS-BI-Phosphate, Fast Red Violet LB Salt, Triton X-100, dimethylformamide) and hemalum ([@B39]).

*Ex vivo* Experiments
---------------------

Mesenchymal stem cells were isolated from femora and tibiae of Thy-1-deficient and WT mice by enzymatic digestion using 26 U/ml of Liberase DL (Roche) for 2 h at 37°C and 5% CO~2~. Cell suspension was filtered through a cell strainer (70 μm) and cultured in a-MEM medium (Lonza) supplemented with 10% fetal calf serum (FCS) (Thermo Fisher Scientific) and 1% penicillin/streptomycin (Biochrom AG) at 37°C, 5% CO~2~. CD11b-positive cells were removed by magnetic cell separation using anti-CD11b magnetic beads according to the manufacturer's protocol (Miltenyi). Purity was checked as described previously ([@B39]). MSCs were stimulated with 10 ng/ml TNF (Miltenyi) for 24 h.

Statistical Analysis
--------------------

The results are presented as mean ± standard deviation (SD). Distribution of data was assessed by Shapiro-Wilk test. Depending on the normality of the data, analysis was performed using the Mann-Whitney rank-sum test or the *t*-test. For assessment of the effect of Thy-1 deficiency and TNFα treatment on MSCs *ex vivo*, we performed two-way ANOVA with Tukey *post hoc* test. *P* \< 0.05 was considered significant.

Results
=======

Obese Thy-1^−/−^ Mice Display Decreased Trabecular Bone Mass While Cortical Bone Mass and Biomechanical Properties Are Unaltered
--------------------------------------------------------------------------------------------------------------------------------

Since diet-induced obesity alters bone remodeling leading to decreased femoral trabecular bone mass in mice ([@B6], [@B7]; [@B16]; [@B38]; [@B41]), we investigated the impact of Thy-1 on the disturbed bone remodeling in obesity. A significantly higher weight gain was observed beginning 12 weeks after starting a HFD in Thy-1^−/−^ compared to WT mice. As control, one group of WT mice was fed a standard chow diet (CHOW, **Figure [1A](#F1){ref-type="fig"}**). The impact of Thy-1 deficiency on characteristics of the femoral and tibial long bones as well as of lumbar vertebral bodies after 18 weeks of HFD was analyzed. Similar to mice fed a HFD for 8 weeks ([@B34]), lack of Thy-1 reduced femoral trabecular bone mass (**Figure [1B](#F1){ref-type="fig"}** and **Supplementary Animation [1](#SM2){ref-type="supplementary-material"}** and **Supplementary Table [2A](#SM1){ref-type="supplementary-material"}**) due to a decreased trabecular number and increased trabecular separation (**Supplementary Table [2A](#SM1){ref-type="supplementary-material"}**). In addition, we could show that in contrast to lean mice, Thy-1 deficiency also reduced bone mass of the lumbar vertebral bodies under obese conditions (**Supplementary Figure [1](#SM1){ref-type="supplementary-material"}** and **Supplementary Table [2D](#SM1){ref-type="supplementary-material"}**).

![Obese Thy-1^−/−^ mice display decreased trabecular bone mass while cortical bone mass and biomechanical properties are unaltered. Wildtype (WT) and Thy-1^−/−^ (KO) mice were fed with a high fat diet for 18 weeks (HFD). As control group, WT mice were fed a standard chow (CHOW) for the same time period. **(A)** The body weight of standard and HFD fed WT and KO mice over 18 weeks. Hashtags denote significance level of \#*P* \< 0.05, \#\#\#*P* \< 0.001 between WT-HFD and WT-CHOW and asterisks denote significance level of ^∗^*P* \< 0.05 between WT-HFD and KO-HFD (Student's *t*-test). **(B)** Representative 3D-images of the trabecular (upper row) and cortical bone compartment (lower row) of the femur. Bone values are presented in **Supplementary Table [2](#SM1){ref-type="supplementary-material"}**. **(C)** Cortical porosity (Ct.Po), **(D)** total indentation distance (TID, reference-point indentation), **(E)** moment of inertia (MOI, μCT calculation), and **(F)** maximum force (F~max~, three-point bending test) to fracture cortical bone were examined. **(G)** Mineral-to-matrix ratio (MMR) and **(H)** carbonate-to-phosphate ratio were analyzed using fourier-transform infrared spectroscopy (FTIR). Each point represents one mouse and median ± SD is presented. Asterisks denote significance level of ^∗^*P* \< 0.05, ^∗∗∗^*P* \< 0.001 (Student's *t*-test).](fcell-06-00127-g001){#F1}

Because HFD-induced obesity often results in an elevated cortical bone mass in humans while fracture risk is highly increased ([@B9]; [@B21]; [@B56]; [@B17]), we analyzed the bone mass and biomechanical properties of the cortical bone compartment. The cortical bone mass and cortical thickness were not altered in obese Thy-1^−/−^ mice (**Figure [1B](#F1){ref-type="fig"}** and **Supplementary Table [2B](#SM1){ref-type="supplementary-material"}**). Cortical porosity was not affected by Thy-1 deficiency after HFD (**Figure [1C](#F1){ref-type="fig"}**). Using reference-point indentation, we detected no differences between WT and Thy-1^−/−^ mice regarding the total indentation distance (TID, **Figure [1D](#F1){ref-type="fig"}**), a marker for hardness of cortical bone ([@B48]). In line with that, the moment of inertia (MOI, **Figure [1E](#F1){ref-type="fig"}**), which is a geometrical parameter that is indicative of resistance to load, and the total tissue area, cortical area, and marrow area (Tt.Ar, Ct.Ar, Ma.Ar, **Supplementary Table [2B](#SM1){ref-type="supplementary-material"}**) as well as the femur length and width (**Supplementary Table [2C](#SM1){ref-type="supplementary-material"}**) were likewise unaffected by Thy-1 deficiency after HFD. By performing a three-point bending test, we could validate the results of the geometric measurement. The same force was needed to fracture the femora from WT and Thy-1^−/−^ mice (**Figure [1F](#F1){ref-type="fig"}**). Moreover, in Thy-1^−/−^ mice, the collagen amount within the bone matrix was decreased, indicated by an elevated mineral-to-matrix ratio (MMR, +8%, **Figure [1G](#F1){ref-type="fig"}**) analyzed by FTIR ([@B3]). Taking into account the decreased tissue mineral density measured by μCT (**Supplementary Table [2](#SM1){ref-type="supplementary-material"}**), the mineral age was younger shown by a reduced carbonate-to-phosphate ratio (CPR, −5%, **Figure [1H](#F1){ref-type="fig"}**).

In summary, in obesity, lack of Thy-1 resulted in reduced bone mass while bone stiffness was not affected.

Lack of Thy-1 Reduces Osteoblast Differentiation as Well as Bone Formation and Increases Osteoclast Differentiation and Bone Resorption in Obese Mice
-----------------------------------------------------------------------------------------------------------------------------------------------------

Bone remodeling is a result of the balanced activity of bone-forming osteoblasts and bone-resorbing osteoclasts resulting in a similar bone formation and resorption rate ([@B11]). Therefore, both the differentiation and activity of osteoblasts and osteoclasts were analyzed in obese Thy-1^−/−^ and obese WT mice.

Concerning bone formation, we observed a diminished number, differentiation and activity of osteoblasts (**Figures [2A--J](#F2){ref-type="fig"}**). The number of osteoblasts (Ob.N/B.Pm, −30%, **Figure [2A](#F2){ref-type="fig"}**) was decreased in obese Thy-1^−/−^ mice, while osteoblast surface per bone surface (Ob.S/BS, **Figure [2B](#F2){ref-type="fig"}**) showed trends toward a reduction compared to the WT mice. In accordance, the gene expression of the osteogenic markers *Runx2* (−27%, **Figure [2C](#F2){ref-type="fig"}**) and *Tnalp* (−60%, **Figure [2D](#F2){ref-type="fig"}**) were decreased in bones of obese Thy-1^−/−^ mice. Reduced serum concentration of the bone formation marker P1NP (−27%, **Figure [2E](#F2){ref-type="fig"}**) indicated an attenuated osteoblast activity. Decreased osteoid surface (OS/B.Pm, −43%, **Figures [2F,G](#F2){ref-type="fig"}**), which indicates impaired mineralization, and decreased bone formation rate (BFR/BS, −57%, **Figures [2H,J](#F2){ref-type="fig"}**) due to a lower mineral apposition rate (MAR, −59%, **Figures [2I,J](#F2){ref-type="fig"}**), substantiated these findings. These data were validated in the lumbar vertebral body shown by a reduced bone formation rate and mineral surface per bone surface (BFR/BS, −51%, MS/BS, −46%, **Supplementary Table [2F](#SM1){ref-type="supplementary-material"}**).

![Lack of Thy-1 reduces osteoblast differentiation as well as bone formation and increases osteoclast differentiation and bone resorption in obese mice. Wildtype (WT) and Thy-1^−/−^ (KO) mice were fed with a high fat diet for 18 weeks (HFD). **(A--J)** Bone formation and (K-O) bone resorption were analyzed. The **(A)** osteoblast number per bone perimeter (Ob.N/B.Pm), **(B)** osteoblast surface per bone surface (Ob.S/BS) were analyzed using histology methods. Gene expression of the osteogenic markers **(C)** runt-related transcription factor 2 (*Runx2*), **(D)** and alkaline phosphatase (*Tnalp*) was analyzed by RT-PCR technique. **(E)** The serum concentration of total procollagen type 1 amino-terminal propeptide (P1NP) was analyzed using ELISA technique and the **(F)** osteoid surface per bone perimeter (Osteid.S/B.Pm) by histology. **(G)** Representative sections of von Kossa/van Gieson staining of bone (black) and cartilage (dense red area close to the bone). **(H)** The bone formation rate per bone surface (BFR/BS) as well as **(I)** mineral apposition rate (MAR) were determined by histomorphometric analysis (double calcein labeling). **(J)** Representative images of calcein labeling (green). **(K)** Osteoclast number per bone perimeter (Oc.N/B.Pm) and **(L)** osteoclast surface per bone surface (Oc.S/BS) were analyzed by staining of tartrate resistant acid phosphatase (TRAP). **(M)** Representative images of TRAP staining (red spots and black arrows = TRAP-positive cell/osteoclast). **(N)** Serum concentration of the bone resorption marker carboxy-terminal collagen crosslinks (CTX) was measured by ELISA technique. **(O)** Gene expression of *Trap* was evaluated via RT-PCR. Each point represents one mouse and median ± SD is presented. Asterisks denote significance level of ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01, ^∗∗∗^*P* \< 0.001 (Student's *t*-test).](fcell-06-00127-g002){#F2}

In parallel to the analysis of osteoblast differentiation and activity in obese Thy-1^−/−^ mice, we examined the impact of Thy-1 on bone resorption. Indeed, osteoclast number (Oc.N/B.Pm, +39%, **Figures [2K,M](#F2){ref-type="fig"}**) and surface (Oc.S/BS, +36%, **Figures [2L,M](#F2){ref-type="fig"}**) were increased in the tibia and lumbar vertebral body (**Supplementary Table [2G](#SM1){ref-type="supplementary-material"}**) in obese Thy-1^−/−^ mice. Additionally, the concentration of CTX, a serum bone resorption marker, was elevated (+30%, **Figure [2N](#F2){ref-type="fig"}**). Correspondingly, we observed an elevated gene expression of *Trap*, a marker of osteoclast activity (+86%, **Figure [2O](#F2){ref-type="fig"}**), in bone of obese Thy-1^−/−^ mice.

Lack of Thy-1 Promotes Obesity Mediated Inflammation
----------------------------------------------------

There is accumulating evidence that excessive adipose tissue accumulation in obesity is detrimental to bone health. Indeed, Thy-1^−/−^ mice gained more weight compared to controls after HFD ([@B52]; [@B34]; [@B39]; **Figure [1A](#F1){ref-type="fig"}**). In addition to an increased adipocyte number (N.Adipo, +2.5-fold, **Figure [3A](#F3){ref-type="fig"}**), we observed an elevated adipocyte area (Adipo.Ar, +4-fold%, **Figure [3B](#F3){ref-type="fig"}**) as well as an upregulated gene expression of the fat marker *Fabp* in bone of obese Thy-1^−/−^ mice (+1-fold, **Figure [3C](#F3){ref-type="fig"}**). Altogether an increased total fat volume (FV/TV, +56%, **Figures [3D,E](#F3){ref-type="fig"}**) was observed indicating expanded bone marrow adiposity in Thy-1^−/−^ mice. Increased body fat mass is associated with latent inflammatory response ([@B15]). Consistent with this, the gene expression of the potent pro-inflammatory cytokines *Tnfα* and *Il6* (+130 and +46%, respectively, **Figures [3F,G](#F3){ref-type="fig"}**) were elevated in obese Thy-1^−/−^ mice. Indeed, TNFα strongly increased osteoclast differentiation shown by an increased number of multinucleated, TRAP positive giant cells (**Figure [3H](#F3){ref-type="fig"}**).

![Lack of Thy-1 promotes obesity mediated inflammation. Wildtype (WT) and Thy-1^−/−^ (KO) mice were fed with a high fat diet for 18 weeks (HFD). **(A)** Number of adipocytes per total area (N.Adipo/Tt.Ar) and **(B)** adipocyte area (Adipo.Ar) of adipocytes were analyzed by histology technique. **(C)** Gene expression of the fat marker fatty-acid-binding protein (*Fabp*) in bone was assessed by RT-PCR. **(D)** Fat volume (FV/TV) in the femoral medullary cavity was analyzed by osmium tetroxide staining. **(E)** Representative 3D-images of the fat volume of whole femur. **(F,G)** Gene expression of the pro-inflammatory markers tumor necrosis factor α (*Tnfα*) and interleukin 6 (*Il6*). **(H)** Osteoclast precursor cells from WT mice were cultured *ex vivo* without (w/o) and with TNFα and osteoclastogenesis was detected via staining for tartrate resistant acid phosphatase (TRAP; giant, multinucleated, red cells = osteoclasts; indicated by arrows). Asterisks denote significance level of ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01 (Student's *t*-test).](fcell-06-00127-g003){#F3}

Thy-1^−/−^ in Obesity Does Not Alter the Wnt and YAZ/TAZ Pathway
----------------------------------------------------------------

Osteogenic differentiation and bone formation is strongly regulated by Wnt signaling that is controlled by inhibitor molecules such as Dkk-1 and sclerostin ([@B42]; [@B25]). However, gene expression of *Dkk-1* and sclerostin (*Sost*, **Figures [4A,B](#F4){ref-type="fig"}**) as well as their serum concentrations (**Figures [4C,D](#F4){ref-type="fig"}**) were unaffected in obese Thy-1^−/−^ mice. In line with these observations, the gene expression of non-canonical, *Wnt5a* and *Wnt11*, as well as canonical Wnt ligands, *Wnt3a* and *Wnt10b*, were not altered in bone by Thy-1 deficiency after HFD (**Figures [4E--H](#F4){ref-type="fig"}**). The Hippo signaling increases osteoblastogenesis ([@B36]). Neither Thy-1 deficiency nor treatment with TNFα altered gene expression of YAP or TAZ in wildtype and Thy-1^−/−^ MSCs (**Figures [4I,J](#F4){ref-type="fig"}**).

![Thy-1^−/−^ in obesity does not alter the Wnt and YAZ/TAZ pathway. Wildtype (WT) and Thy-1^−/−^ (KO) mice were fed with a high fat diet for a time period of 18 weeks (HFD). Gene expression of the Wnt pathway inhibitors **(A)** dickkopf-1 (*Dkk-1*) and **(B)** sclerostin (*Sost*) and **(C,D)** their serum concentrations were evaluated by RT-PCR and ELISA technique, respectively. Gene expression of Wnt ligands such as **(E)** *Wnt5a*, **(F)** *11*, **(G)** *3a*, and **(H)** *10b* in bone was analyzed by RT-PCR. MSCs from WT and Thy-1^−/−^ mice were treated with TNFα and expression of *Yap* and *Taz* of the hippo signaling were investigated. Statistical analysis was performed by **(A--H)** Student's *t*-test and by **(I,J)** 2-way ANOVA.](fcell-06-00127-g004){#F4}

In summary, Thy-1 does not alter bone formation by modulation of the Wnt pathway nor the Hippo signaling in Thy-1^−/−^ mice.

Lack of Thy-1 in Obese Mice Alters the Gene Expression of RANKL, OPG, and CSF1 Under Inflammatory Conditions
------------------------------------------------------------------------------------------------------------

Since the RANK-RANKL-OPG axis and binding of CSF1 to its receptor CSF1R, located at surface of osteoclasts, play central roles in osteoclastogenesis, we analyzed their gene expression in bone of WT and Thy-1^−/−^ mice. The gene expression of *Tnfsf11*, which encodes for RANKL, was unaffected, while the expression of its decoy receptor *Tnfrsf11b*, encodes for OPG (*p* = 0.07) showed trend toward reduction in bone of obese Thy-1^−/−^ mice (**Figures [5A,B](#F5){ref-type="fig"}**). The expression of *Csf1* was not detectable in bone, but the expression of its receptor *Csf1r* showed a trend toward upregulation (*p* = 0.07, **Figure [5C](#F5){ref-type="fig"}**). Obesity is characterized by latent inflammation shown by increased TNFα levels. Since RANKL, OPG, and CSF1 are expressed by stromal cells in bone, we stimulated WT and Thy-1^−/−^ MSCs with TNFα to mimic the pro-inflammatory environment. Gene expression analysis revealed that Thy-1 does not affect the expression of *Tnfsf11*, *Tnfrsf11b*, and *Csf1* under basal conditions (**Figures [5D--F](#F5){ref-type="fig"}**). Upon pro-inflammatory stimulation, Thy-1^−/−^ MSCs expressed reduced levels of *Tnfrs11b* (−36%, **Figure [5E](#F5){ref-type="fig"}**) while *Csf1* (+37%, **Figure [5F](#F5){ref-type="fig"}**) expression was elevated.

![Lack of Thy-1 in obese mice alters the gene expression of RANKL, OPG, and CSF1 under inflammatory conditions. Wildtype (WT) and Thy-1^−/−^ (KO) mice were fed with a high fat diet for a time period of 18 weeks (HFD). **(A)** Gene expression of receptor activator of NF-κB ligand (RANKL, *Tnfsf11*), **(B)** its decoy receptor osteoprotegerin (OPG, *Tnfrsf11b*), and **(C)** receptor of Csf1 *(Cfs1r)* was analyzed in bone. MSCs from WT and KO mice were treated with TNFα for 24 h to mimic an inflammatory environment and gene expression of *Tnfsf11*, *Tnfrsf11b*, and *Cfs1* was determined **(D--F)**. **(G)** Summary figure of the key findings. In mice, Thy-1 deficiency results in a reduced osteoclastogenesis and increased adipogenesis leading to a decreased bone formation. Adipocytes produce more of the pro-inflammatory cytokine TNFα and the RANKL-OPG ratio is reduced resulting in an elevated osteoclastogenesis and poor bone mass. Each point represents one mouse and median ± SD is presented. Asterisks denote significance level of ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01, ^∗∗∗^*P* \< 0.001 measured by **(A--C)** Student's *t*-test and by **(D--F)** 2-way ANOVA.](fcell-06-00127-g005){#F5}

Taken together, Thy-1 leads to an unaltered *Tnfsf11*, reduced *Tnfrsf11b*, and increased *Csf1* expression in an inflammatory environment that might contribute to increased osteoclastogenesis in Thy-1^−/−^ mice.

Discussion
==========

Alterations in bone mass and quality caused by osteoporosis and obesity are major health problems worldwide. They are caused by an unbalanced differentiation capacity and activity of bone-forming osteoblasts and bone-resorbing osteoclasts. The underlying mechanisms are still not fully understood and therefore sufficient therapy options are limited. One step toward identifying these mechanisms was the recent discovery that the cell-surface protein Thy-1 is a major modulator of MSC differentiation into the adipogenic or osteogenic lineage ([@B19]; [@B8]; [@B39]). In lean mice, Thy-1 deficiency increases whole body adipogenesis while decreasing osteoblast differentiation resulting in poor bone mass and quality indicating Thy-1 as a protector of bone mass ([@B52]; [@B39]). Therein, the activity of osteoclasts was not altered. Here, we went one step further and analyzed Thy-1 effects on bone under obese conditions. Thy-1^−/−^ and WT mice fed a HFD developed an obese phenotype whereas Thy-1 deficiency exacerbated fat accumulation. Most importantly, Thy-1 deficiency decreased the bone mass under obese conditions by affecting both bone formation and bone resorption.

Thy-1 has been shown to promote osteogenesis and thereby inhibit adipogenesis ([@B19]; [@B8]; [@B52]; [@B39]). More specifically, inhibition of Thy-1 expression in MSCs isolated from different sources resulted in increased adipogenic differentiation mirrored by enhanced lipid droplet accumulation ([@B31]). Moreover, ectopic expression of Thy-1 in adipocyte-like 3T3 cells inhibits adipogenic differentiation while depletion of endogenous Thy-1 in human fibroblasts increases their ability to undergo adipogenesis ([@B52]; [@B39]). Correspondingly, Thy-1^−/−^ mice show an increased weight gain and body fat mass caused by inhibiting the activity of the Fyn kinase resulting in a reduced expression of PPARγ ([@B52]; [@B39]). On the other hand, Thy-1-positive MSCs, adipose-derived stromal cells and dental pulp cells show an increased ALP activity and mineralization capacity *in vitro* ([@B19]; [@B8]; [@B39]). Upon subcutaneous injection, these cells increase formation of bone-like matrix and improve the healing of critical size defects ([@B19]; [@B8]). In contrast, [@B31] demonstrated that Thy-1 downregulation supports osteogenic differentiation of dental pulp cells and MSCs but, however, detected concurrently an increased adipogenic differentiation of cells with decreased Thy-1 expression. Importantly, we recently demonstrated that Thy-1^−/−^ mice have a massive reduction of bone mass and quality independent of the gender when fed a standard chow ([@B39]).

In the present study, we demonstrated that Thy-1 deficiency augmented obesity-mediated bone loss. In agreement with [@B34] we found a reduced femoral bone volume and microstructure due to a decreased trabecular number and increased trabecular separation. Interestingly, bone mass of vertebral bodies was not altered in lean Thy-1^−/−^ mice, but reduced in obese Thy-1^−/−^ mice. This is an interesting finding as other studies also report varying effects on femur and vertebral bodies in rodent experiments. The negative effect of osteoporosis induced by ovariectomy on bone mass was found to be more pronounced in femur neck compared to the spine ([@B23]). One reason could be that the spine of quadrupeds is in a horizontal position and could be therefore exposed to less mechanical loading in comparison to the femur ([@B47]). The increased mechanical loading brought about by weight gain in lean Thy-1^−/−^ mice may not have been sufficient to affect trabecular bone mass at sites other than the femur.

In lean Thy-1^−/−^ mice, the cortical bone mass and its biomechanical properties were significantly reduced compared to WT controls ([@B39]). In contrast, HFD and Thy-1 deficiency did not alter the cortical bone mass. Consequently, bone quality markers such as cortical porosity and the moment of inertia were not affected by Thy-1 deficiency under obese conditions. Thy-1-mediated effects on cortical bone therefore seem to be compensated by as yet unknown mechanisms in obesity. In addition, in lean mice, Thy-1 deficiency was accompanied by increased expression of Wnt inhibitors, reduced expression of Wnt ligands and reduced responsiveness to Wnt stimulation ([@B39]). However, obesity seems to overwrite these Thy-1-mediated effects on the Wnt pathway. Further, osteo-anabolic Hippo signaling was also not altered by neither Thy-1 deficiency nor mimicked the pro-inflammatory environment *ex vivo*.

Bone remodeling is a result of the balanced bone formation by bone-forming osteoblasts and bone resorption by bone-resorbing osteoclasts ([@B11]). As shown in lean and obese mice Thy-1 deficiency reduced the number and activity of osteoblasts and thus impaired bone formation ([@B34]; [@B39]). Interestingly, in lean mice, lack of Thy-1 neither affected number nor activity of osteoclasts. In contrast, upon 18 weeks of HFD Thy-1 deficiency enhanced the number and activity of osteoclasts and, thus, might force bone resorption. This might contribute to bone loss in obese Thy-1 deficient mice. Interestingly, [@B34] described a reduction of osteoblasts in obese Thy-1^−/−^ mice while osteoclasts were unaffected. However, [@B34] analyzed mice upon 8 weeks of HFD. In our study, Thy-1 deficiency induced an enhanced weight gain from 12 weeks of HFD. Thus, Thy-1 deficiency impaired osteoblast differentiation and activity under both lean ([@B39]) body composition and in the early and late phase of obesity. In contrast, an impact of Thy-1 deficiency on osteoclasts was only seen in late, distinct obesity.

Obesity is associated with latent inflammatory responses indicated by an elevated expression of pro-inflammatory cytokines such as Il1, Il6, and TNFα ([@B5]). Indeed, we detected an increased bone marrow adiposity in obese Thy-1^−/−^ mice. Correspondingly, gene expression of *Il6* and *Tnfα* was up-regulated in the bone of obese Thy-1^−/−^ compared to obese WT mice. IL-6 can be produced by osteoblasts and induces bone resorption ([@B22]). TNFα expression has been shown to be increased in obesity, arthritis, and osteoporosis. TNFα is able to affect both osteoclast differentiation and osteogenesis. TNFα produced by adipocytes potently reduces the differentiation of osteoblasts via TNFR1 or via upregulation of autophagy and reduction of apoptosis ([@B13], [@B14]; [@B55]; [@B1]; [@B57]). In obesity, arthritis, and osteoporosis, which are diseases that are characterized by a reduction of bone mass due to an increased osteoclastogenesis ([@B5]; [@B16]; [@B45]). TNFα has the ability to increase osteoclast differentiation by elevating the expression of RANKL, a master modulator of osteoclastogenesis, by osteoblasts via TNFR1 and/or by the Pi3K/Akt pathway ([@B54]; [@B46]; [@B26]; [@B33]; [@B53]). TNFα alone does not increase the differentiation of osteoclast precursor cells ([@B29]; [@B30]), but has been shown to act synergistically together with RANKL on osteoclastogenesis ([@B2]; [@B30]; [@B12]). In addition, TNFα can also elevate osteoclast differentiation when CSF1 is present ([@B29]; [@B27]). *Ex vitro*, we demonstrated the augmentation of osteoclastogenesis by TNFα in the presence of RANKL and CSF1. Thus, despite of similar expression of *Tnfsf11* (RANKL) in bone of obese WT and Thy-1-deficient mice elevated amounts of TNFα in Thy-1-deficient mice might contribute via the synergistic action with RANKL to increased osteoclast number and activity in Thy-1 deficient mice.

In addition to the RANK-RANKL-OPG axis, the presence of CSF1 is essential for osteoclast differentiation ([@B24]). The reduced expression of RANKL decoy receptor, *Tnfsf11b* (OPG) and increased expression of *Csf1* under pro-inflammatory conditions in Thy-1^−/−^ MSC might contribute to the increased osteoclastogenesis in obese Thy-1^−/−^ mice.

However, one limitation of our study is that we could not demonstrate a direct relation *in vivo* between alteration of TNFα, CSF1, and OPG expression in obese Thy-1^−/−^ mice and increased osteoclastogenesis and diminished bone mass. Because we were working with a global knockout mouse model, we cannot fully exclude effects of other cell types expressing Thy-1 on bone metabolism. Nevertheless, we showed previously that isolated MSCs from lean Thy-1^−/−^ mice created less mineralized matrix in a WT environment *in vivo* ([@B39]). However, we failed to discover the underlying mechanism of reduced osteoblastogenesis in Thy-1 deficiency in obese mice. It is known that obese patients have an increased concentration of unsaturated fatty acids that negatively affect osteoblastogenesis ([@B18]). In future, it should be addressed if this could also affect differentiation and function of Thy-1^−/−^ MSCs.

Taken together, Thy-1 controls the balance between bone formation and bone resorption. In lean mice and in the early phase of obesity, a lack of Thy-1 impairs bone formation by inhibition of osteoblast differentiation, while there is no effect on bone resorption ([@B34]; [@B39]). In the present study, we show that a lack of Thy-1 under manifest obese conditions affects both bone formation and bone resorption. Obese Thy-1^−/−^ mice exhibited increased bone marrow adiposity associated with an increased pro-inflammatory environment including increased *Tnfa* expression. TNFα is a strong promotor of osteoclast differentiation and, thus, bone resorption. On the other hand lack of Thy-1 resulted in an attenuated expression of *Tnfsf11B* (OPG), the decoy receptor for *Tnfsf11* (RANKL). Both increased TNFα expression and diminished *Tnfsf11B* might induce bone resorption in obese Thy-1^−/−^ mice (**Figure [5G](#F5){ref-type="fig"}**).
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